Immune Design Corp. (NASDAQ:IMDZ) shares traded down 1.9% during mid-day trading on Friday . The company traded as low as $7.00 and last traded at $7.24, with a volume of 82,898 shares. The stock had previously closed at $7.38.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Immune Design Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Leerink Swann reaffirmed a “buy” rating on shares of Immune Design Corp. in a report on Friday, June 10th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 target price on shares of Immune Design Corp. in a report on Sunday, May 29th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Immune Design Corp. currently has a consensus rating of “Buy” and a consensus price target of $24.00.

The company’s market cap is $144.30 million. The firm has a 50-day moving average price of $8.82 and a 200 day moving average price of $11.48.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.01. Equities analysts expect that Immune Design Corp. will post ($2.70) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Immune Design Corp. stock. Jennison Associates increased its position in shares of Immune Design Corp. (NASDAQ:IMDZ) by 0.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 202,683 shares of the company’s stock after buying an additional 1,224 shares during the period. Jennison Associates owned approximately 1.01% of Immune Design Corp. worth $2,473,000 as of its most recent SEC filing.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.